Core Viewpoint - The announcement details the adjustment of the conversion price for the company's convertible bonds due to the implementation of a profit distribution plan for the first half of 2025, resulting in a decrease in the conversion price from 16.46 CNY to 16.26 CNY per share [2][3][6]. Group 1: Conversion Price Adjustment - The initial conversion price of the "Huakang Convertible Bonds" was set at 22.66 CNY per share, which has undergone several adjustments due to various corporate actions [5]. - The conversion price was adjusted to 16.89 CNY per share on May 28, 2024, and further adjusted to 16.39 CNY on April 24, 2025, before the latest adjustment [5]. - The new conversion price of 16.26 CNY per share will take effect on September 29, 2025, following the distribution of a cash dividend of 0.2 CNY per share [3][6]. Group 2: Profit Distribution Plan - The company plans to distribute a cash dividend of 0.2 CNY per share, amounting to a total of approximately 6,060.99622 million CNY based on the total share capital of 30,304.9811 million shares [11][13]. - The profit distribution plan was approved during the second extraordinary general meeting of shareholders held on September 8, 2025 [11]. - The distribution will be executed through the Shanghai Clearing House, with specific procedures outlined for both unrestricted and restricted shareholders [14][16].

Core Viewpoint - Zhejiang Huakang Pharmaceutical Co., Ltd. plans to distribute a cash dividend of 2 yuan (including tax) for every 10 shares, based on the total share capital registered on the equity distribution date [1][2]. Summary by Sections Profit Distribution and Capital Increase Plan - As of June 30, 2025, the company has a distributable profit of 1,174.4735 million yuan [1]. - The proposed cash dividend distribution is based on the total share capital as of the equity distribution registration date, which is 30,304.9751 million shares as of August 20, 2025 [1]. - The cash dividend represents 45.33% of the company's net profit attributable to shareholders, with no capital increase from reserves planned [1]. Decision-Making Process - The company held the 32nd meeting of the sixth board of directors and the 21st meeting of the sixth supervisory board on August 21, 2025, where the profit distribution proposal was approved [2]. - The supervisory board believes the profit distribution plan considers the company's operational and financial status and aligns with relevant regulations, supporting sustainable development without harming the interests of the company and investors [2]. Additional Notes - If there are changes in total share capital due to convertible bonds, share buybacks, or other factors before the equity distribution registration date, the per-share distribution ratio will remain unchanged, and the total distribution amount will be adjusted accordingly [2]. - The profit distribution proposal is subject to approval at the company's second extraordinary general meeting of shareholders in 2025 [2].

Core Points - The announcement details the conversion results of the "Huakang Convertible Bonds" issued by Zhejiang Huakang Pharmaceutical Co., Ltd. as of June 30, 2025 [1] Summary by Sections Convertible Bond Issuance Overview - The company issued convertible bonds on December 25, 2023, with a total scale of RMB 1,303.023 million, with a face value of RMB 100 per bond [4] - The bonds have a maturity period of up to 6 years, from December 25, 2023, to December 24, 2029, with a tiered interest rate structure [4] Conversion Status - As of June 30, 2025, a total of RMB 778,000 of the "Huakang Convertible Bonds" has been converted into company shares, representing 0.0597% of the total bond issuance [2][7] - The number of shares converted is 46,054, which is 0.0151% of the total shares outstanding before conversion [2][7] - No conversions occurred during the quarter from April 1, 2025, to June 30, 2025 [3][6] Unconverted Bonds - As of June 30, 2025, the amount of unconverted "Huakang Convertible Bonds" stands at RMB 1,302.245 million, accounting for 99.9403% of the total issuance [3][7] Share Price Adjustments - The initial conversion price was set at RMB 22.66 per share, which was adjusted to RMB 16.89 on May 28, 2024, and further adjusted to RMB 16.39 on April 24, 2025, and to RMB 16.46 on May 14, 2025, due to various corporate actions [4][5]

Core Points - The company's bond credit rating remains "AA-" and the issuer credit rating is also "AA-" with a stable outlook [1][2] - The previous ratings were confirmed with no changes in the current assessment [2] Summary by Sections Credit Rating - The previous bond credit rating was "AA-" and the issuer credit rating was "AA-" with a stable outlook [1] - The current bond credit rating is "AA-" and the issuer credit rating is "AA-" with a stable outlook, indicating no change from the previous rating [2] Rating Agency - The credit rating was conducted by Zhongzheng Pengyuan Credit Rating Co., Ltd. [2] - The comprehensive analysis and evaluation of the company's operational status were the basis for the rating [2] Reporting - The tracking credit rating report for the company's convertible bonds is available on the Shanghai Stock Exchange website [2]

Core Points - The company has completed the repurchase and cancellation of certain restricted stocks and adjusted the conversion price of "Huakang Convertible Bonds" [1][5] Group 1: Stock Repurchase and Cancellation - The company has approved the repurchase and cancellation of 2,832,700 shares of restricted stock that do not meet the release criteria [4][5] - The repurchase was conducted under the 2023 Restricted Stock Incentive Plan [4] Group 2: Adjustment of Conversion Price - The conversion price of "Huakang Convertible Bonds" has been adjusted from 16.39 CNY/share to 16.46 CNY/share, effective from May 14, 2025 [2][5] - The adjustment is based on the repurchase of restricted stocks and follows the formula for conversion price adjustment as outlined in the company's prospectus [3][5] - The average repurchase price calculated was approximately 9.36 CNY/share, leading to a slight increase in the conversion price [5]

| | 修订前 | 修订后 | | | --- | --- | --- | --- | | 第六条 | 公司注册资本为人民币 | 第六条 | 公司注册资本为人民币 | 1 | 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-019 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 浙江华康药业股份有限公司 关于减少公司注册资本并修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华康药业股份有限公司（以下简称"公司"）于 2024 年 12 月 9 日召开 第六届董事会第二十六次会议、第六届监事会第十七次会议，审议通过《关于回 购注销 2023 年限制性股票激励计划部分限制性股票的议案》，鉴于本激励计划中 的 1 名激励对象考核结果为不合格，根据《华康股份 2023 年限制性股票激励计 划（草案）》（以下简称《激励计划》）的相关规定，公司董事会同意对其持有 的已获授但不符合解除限售标准的 11,700 股限制性股票予以回 ...